39 results about "Pulmonary emphysema" patented technology

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses a lung abnormal region detection method, device and equipment based on an attention mechanism. The method comprises the following steps: acquiring a lung image to be detected; the trained GLA-YOLO network is adopted to detect a lung abnormal region in the lung image to be detected, and a detection result of the lung image to be detected is obtained; the detection result comprises whether lung abnormal areas exist or not and the abnormal category of each lung abnormal area; wherein the GLA-YOLO network is a network obtained by improving the network structure of a YOLOV8 network, and a channel attention module, a space attention module and a C3E module based on a self-attention mechanism are fused in the GLA-YOLO network. According to the method, the detection precision of the lung abnormal region related to emphysema in the lung image can be remarkably improved.

The present invention relates to a novel method of treating pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency (AATD), a genetic disorder that causes low levels of alpha-1 antitrypsin (AAT), a protein that protects the lungs from damage by neutrophil elastase. The invention consists of aerosolizing nanoparticles composed of apolipoprotein A1 enriched with AAT (A1NP). The invention aims to deliver these nanoparticles directly to the lungs, where they can interact with the alveolar surface and modulate the inflammatory and proteolytic processes that lead to emphysema. In particular, the inventors report that said nanoparticles are not cytotoxic, have anti-inflammatory and anti-elastase properties, can cross alveolar epithelial cells, and are not immunogenic in mice.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating chronic obstructive pneumonia and a pharmaceutical preparation. The traditional Chinese medicine composition comprises blackberry lily, honey-fried ephedra, dried ginger, asarum, honey-fried aster, honey-fried tussilago farfara, exocarpium citri rubrum, schisandra chinensis, fried semen raphani, perillaseed, semen brassicae and liquorice. The traditional Chinese medicine composition and the pharmaceutical preparation provided by the invention are used for patients with chronic obstructive pneumonia, can recover the pulmonary ventilation function, effectively inhibit inflammatory response in the body and promote lung tissue injury repair, and have a relatively good treatment effect on chronic obstructive pneumonia.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a pharmaceutical composition for treating hormone-resistant severe asthma and application of the pharmaceutical composition. The invention relates to an application of pentagalloylglucose (PGG) in preparation of a medicine for treating or preventing hormone-resistant severe asthma. The traditional Chinese medicine composition has a better effect on emphysema caused by severe asthma. The invention reveals and verifies that intestinal injury is a key upstream factor causing severe asthma and hormone resistance for the first time. Through targeted repair of intestinal tracts, the PGG can fundamentally remodel the immune microenvironment of the lung, and creates conditions for hormone to play a role. The discovery breaks through the limitation that traditional asthma treatment only focuses on local targets of the respiratory tract, and a brand new theoretical basis and a feasible solution are provided for overcoming the worldwide problem of hormone resistance.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

This invention relates to the application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). The mitochondrial formulations contain active mitochondria isolated from healthy donor cells, with a particle size of 400–1000 nm, possessing normal mitochondrial membrane potential and ATP generation function, and capable of being internalized by mammalian COPD lung epithelial cells. In vitro cell experiments have confirmed that this mitochondrial formulation can repair CSE-induced mitochondrial dysfunction in lung epithelial cells, inhibit mPTP opening, reduce mtDNA leakage into the cytoplasm, thereby blocking the activation of the cGAS-STING signaling pathway and reducing the release of inflammatory factors such as IL-1β and TNF-α. In vivo experiments in COPD mouse models show that tail vein injection of the mitochondrial formulation can effectively accumulate in lung tissue, significantly improving lung pathological changes such as emphysema and collagen fiber deposition in model mice. This invention provides a novel strategy for COPD treatment based on repairing mitochondrial function and intervening in inflammatory signaling pathways.

The application provides an adjustable medical instrument device, relates to the technical field of lung volume reduction instrument, and comprises an elastic implant body, an adjusting wire is arranged in the elastic implant body, and the adjusting wire extends along a preset shape of the elastic implant body; a first end of the adjusting wire is fixed at a proximal end of the elastic implant body, and a second end opposite to the first end of the adjusting wire is fixed at a distal end of the elastic implant body; wherein, the adjusting wire is provided with a pre-tightening force, so that the elastic implant body is close from the distal end to the proximal end, and the compression force of the elastic implant body acting on a target emphysema position is adjusted. Through the lung volume reduction instrument provided by the application, the problem that the compression force of the lung volume reduction instrument on the market is fixed and limited, the preset shape is insufficient, the residual air of the target emphysema position is not completely discharged, and the volume reduction effect is poor is solved.

The present invention relates to a novel Lactobacillus fermentum HEM20792 strain, a composition comprising the strain or a culture thereof for preventing or treating chronic obstructive pulmonary disease (COPD), and the like. The composition comprising a Lactobacillus fermentum HEM20792 strain (KCTC14066BP) as an active ingredient, according to the present invention, inhibits lung tissue damage and suppresses immune cells, and thus can prevent or treat COPD including emphysema. Therefore, it is expected that the present invention can be used to help cure pulmonary disease by eliminating a fundamental cause of COPD.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The utility model discloses a kind of metal frame processing anti-deviation welding equipment, including welding frame, the inside movable mounting of welding frame has reciprocating screw rod, the both sides of reciprocating screw rod are provided with guide vane, the inside movable of welding frame is provided with transmission seat, transmission seat is fixed with welding gun and is inserted in the inside, the end outer side of welding gun is installed with negative pressure hopper, negative pressure hopper includes the fixed disc installed in the end outer side of welding gun, the outside of fixed disc is covered with smoke suction disc, smoke suction disc end is fixedly provided with negative pressure pipe.The metal frame processing anti-deviation welding equipment, smoke suction disc is wide in front and narrow in back, the front end of front width can expand smoke capture range, form larger negative pressure adsorption area near welding gun, effectively cover the smoke diffusion range generated when welding;Reduce workshop smoke escape;Avoid the situation that staff long-term inhalation can cause welder pneumoconiosis, chronic bronchitis, emphysema and other respiratory diseases.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound GLP-4 that has a clear molecular structure and has the effects of treating emphysema and pulmonary fibrosis and resisting tumors, which polysaccharide compound has a molecular formula of: (C162H270O135)n. Ganoderma is subjected to high-temperature and high-pressure extraction using an alkali solution, the resulting medicine residues are extracted, and then separation is performed by column chromatography to obtain the polysaccharide compound. The polysaccharide compound has a good water solubility, is easily absorbed by a human body, has better effects than pirfenidone in terms of the treatment of emphysema and pulmonary fibrosis, and also has efficacy in patients with advanced cancers (patients who have lost surgical condition, have a survival time of only three to six months, and still have chemotherapy condition). Especially when being used in combination with a chemotherapeutic drug, the polysaccharide compound can eliminate the toxic side effects caused by the chemotherapeutic drug in the human body, and can be used for controlling and reducing a tumor mass, and reducing and eliminating tumor cells, which effects are all supported by corresponding experimental data.

The invention discloses a cold region chronic obstructive pulmonary disease risk prediction method, electronic equipment and a storage medium. The cold region chronic obstructive pulmonary disease risk prediction method comprises the steps of obtaining conventional indexes of a person to be predicted; and inputting the conventional indexes into a preset COPD risk prediction model so as to predict and display the disease risk of the to-be-predicted person. Wherein the conventional indexes comprise age, smoking condition, drinking condition, chronic bronchitis and emphysema history, airflow blocking condition, average diastolic pressure, heart rate and BMI. The conventional indexes can be obtained without depending on expensive special equipment (such as imaging equipment) or complex biomarker detection, so that the data acquisition cost and the operation difficulty are greatly reduced. The preset COPD risk prediction model is constructed based on an XGBoost model and a Logistic Regression model, so that efficient and accurate COPD disease risk prediction can be realized, and the applicability of the model can be improved.

The present invention relates to a metered dose inhaler device comprising a stable inhalable composition of ipratropium bromide, contained in a canister fitted with a metering valve, an actuator and a dose indicator. The present invention also relates to a process for preparing such a pharmaceutical composition and its use in the treatment of respiratory disorders such as for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in a subject in need thereof (e.g., a human).

Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and / or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and / or acute respiratory distress syndrome.

The present application belongs to the field of artificial pneumothorax making device, and particularly relates to an artificial pneumothorax puncture device for chest wall puncture and establishment of a pleural cavity channel. In view of the defects that the existing puncture needle is easy to puncture the visceral pleura, the position of the needle tip is ambiguous, iatrogenic pneumothorax, gas embolism and other complications are easily caused, and the puncture needle cannot be adapted to high-risk patients such as emphysema, the present application adopts a coaxial structure, designs a blunt and smooth pneumothorax needle, and / or increases the contact area of the front end of the outer sleeve tube with the visceral pleura, cooperates with the side wall vent hole to realize direct positioning of the pleural cavity negative pressure, integrates double operation paths, and is matched with frosted development, scale marking and other optimizations. The device can greatly reduce the risk of complications, expand the applicable population, shorten the positioning time, balance the operation flexibility and accuracy, and effectively improve the safety and efficiency of the artificial pneumothorax operation.

The invention provides a chronic obstructive pulmonary screening auxiliary diagnosis system based on multi-source data, and belongs to the technical field of medical diagnosis, and the system comprises a data collection module which is used for collecting related data of a patient, and the related data comprises a chest CT image and a lung function index; the lung function index comprises a ventilation function index; the data construction module responds to the related data and is used for constructing at least six emphysema observation points according to the acquired chest CT images and acquiring CT images corresponding to the emphysema observation points from the acquired chest CT images; and the feature extraction module is used for extracting features in the CT images corresponding to the emphysema observation points, and the extracted features comprise morphological features. Through multi-source data fusion, dynamic monitoring and quantitative analysis, the accuracy and efficiency of chronic obstructive pulmonary disease screening are improved, and a scientific and reliable auxiliary diagnosis tool is provided for clinic.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

Devices, methods, and systems are provided for analyzing lung imaging data. Lung imaging data maybe analyzed to segment the lung, identify fissure locations, calculate fissure defect scores, identify adjacent lung compartments, calculate emphysema scores, calculate volumes, and calculate proximities. Collateral ventilation within a lung compartment may be determined based on the analyzed lung imaging data.

Nitrile derivative compounds represented by Chemical Formula I, stereoisomers thereof, deuteration products, cocrystals, solvates, or pharmaceutically acceptable salts are provided, wherein each group is defined as in the detailed description. The compounds have dipeptidyl peptidase 1 inhibitory activity and can be used to manufacture drugs for treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, chronic obstructive pulmonary disease and other diseases. [Chemical Formula I]

The present disclosure relates to the technical field of medical images, and discloses a lung lesion identification method and device and an electronic device. The method comprises: acquiring a scan image of a patient's lung, identifying a pulmonary artery region and a pulmonary vein region of the lung in the scan image; acquiring a size parameter of each blood vessel in the pulmonary artery region and the pulmonary vein region, calculating a blood vessel feature of each blood vessel region according to the size parameter of each blood vessel in the pulmonary artery region and the pulmonary vein region; fusing the blood vessel feature of each blood vessel region with a previously acquired lung parenchyma structure feature of the patient's lung to obtain a fused feature; and inputting the fused feature into a previously trained classifier to identify a lung lesion evaluation result of the patient. The above method distinguishes the pulmonary artery and vein, quantifies the features, fuses the emphysema and airway multi-dimensional lesion indicators, and improves the comprehensiveness and accuracy of lung lesion identification. Meanwhile, the method does not require complex data support, simplifies the process, and reduces application costs.

The application discloses application of fresh bamboo juice effective part in preparation of a medicine for treating chronic obstructive pulmonary disease, and belongs to the technical field of medicines.The fresh bamboo juice effective part contains phenolic substances such as guaiacol, 4-ethylphenol, 4-methylguaiacol, 4-ethylguaiacol, p-vinylguaiacol, 2,6-dimethoxyphenol and dihydroeugenol, and the application has been verified to have the effect of significantly relieving airway mucus hypersecretion caused by the syndrome of external cold and internal fluid retention, can simultaneously inhibit multiple inflammatory factors, and reduce inflammatory infiltration of lung tissue, alleviate emphysema, restore lung tissue elasticity, improve lung function and airway wall thickness, and the like.The application provides a new and effective medicine selection for treatment of chronic obstructive pulmonary disease, and is especially suitable for the disease caused by external cold and internal fluid retention, and has a wide application prospect and important clinical value.

The invention discloses a traditional Chinese medicine for treating cold, cough and lung diseases and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine is prepared by compatibility of various common traditional Chinese medicinal materials such as honeysuckle, wild chrysanthemum flower, mulberry leaf, fritillary bulb and dogwood according to specific parts by weight, and the core treatment principle is clearing away heat and toxic materials, ventilating lung and relieving cough, resolving phlegm and relieving asthma, reinforcing qi and nourishing yin, tonifying spleen and kidney, promoting blood circulation to remove blood stasis and taking both symptoms and root causes into consideration. The preparation method comprises the following five steps: screening and treating raw materials, mixing ingredients, decocting and extracting, filtering and extracting juice, and combining and sub-packaging. The preparation method is simple and convenient in process, easy to operate, free of complex equipment, capable of effectively retaining effective components of the medicinal materials and low in cost. The traditional Chinese medicine is suitable for preventing and treating various lung diseases such as cold, cough, asthma, bronchitis, pulmonary nodule, emphysema, pneumonia and pulmonary tuberculosis, is definite in curative effect and small in side effect, and has remarkable clinical application value and popularization prospect.